SEC Form 4 · accession 0001144204-15-055962
Akari Therapeutics Plc · AKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gur Roshwalb
Officer — Chief Executive Officer · Director
Period of report
Sep 21, 2015
Accepted (ET)
Sep 22, 2015 · 5:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001541157
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Ordinary SharesF1 | $0.3221 | Sep 21, 2015 | A | 32,543,700 | A | — | Sep 21, 2025 | Ordinary Shares | 32,543,700 | 32,543,700 | D |
Explanation of responses
- F1The option vests as to 12.5% of the shares on March 18, 2016 and as to an additional 12.5% of the shares on each six month anniversary thereafter over a period of four years from September 18, 2015, provided that Gur Roshwalb remains employed by the Company on the vesting date, and provided further that a minimum of 25% will vest regardless of his employment status. These options will expire 10 years from issuance.